ELIXA — certainty assessment
Domain-by-domain assessment of the certainty of the evidence this trial contributes.
§4Certainty assessment
§4.1Reasoning by domain
Table 6. Certainty domains, the rating recorded against each, and the reasoning.
| Domain | Rating | Reasoning |
|---|---|---|
| Risk of biasLimitations in the design and conduct of the contributing studies. | No concern | No serious concern identified in this domain. |
| InconsistencyUnexplained heterogeneity of results across contributing studies. | No concern | No serious concern identified in this domain. |
| IndirectnessDifferences between the population, intervention, comparator or outcome studied and those of the assessment question. | No concern | No serious concern identified in this domain. |
| ImprecisionWidth of the confidence interval relative to the decision threshold, and the number of events. | No concern | No serious concern identified in this domain. |
| Publication biasRisk that results were selectively reported or that unpublished studies exist. | No concern | No serious concern identified in this domain. |
§4.2Sponsorship
Manufacturer-sponsored. The Institute does not downgrade certainty for sponsorship as a separate domain, because doing so would double-count risk of bias as conventionally assessed. It records sponsorship on the front matter of every trial abstract, and treats the uniformity of sponsorship across this compound class as a limitation of the evidence base rather than of any individual trial. The reasoning is set out in the methodological review of sponsor-generated evidence.
§4.3What this trial does not establish
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJV, Probstfield JL, Riddle MC, Solomon SD, Tardif JC. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. New England Journal of Medicine 2015;373(23):2247–2257. doi:10.1056/NEJMoa1509225 · PMID 26630143
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.